Xenyhexenic acid

Biochem/physiol Actions XEN445 is a potent and selective inhibitor of endothelial lipase with an IC 50 of 237 nM and high selectivity over hepatic and lipoprotein lipases. In experiments with wild-type mice, XEN445 raised plasma HDL-cholesterol

A selective endothelial lipase inhibitor (IC₅₀ = 237 nM) an oral dose of 30 mg/kg increases HDL cholesterol concentrations by 16% after three days and by 30% after nine days dosing in wild-type mice.

A selective endothelial lipase inhibitor (IC₅₀ = 237 nM) an oral dose of 30 mg/kg increases HDL cholesterol concentrations by 16% after three days and by 30% after nine days dosing in wild-type mice.

A selective endothelial lipase inhibitor (IC₅₀ = 237 nM) an oral dose of 30 mg/kg increases HDL cholesterol concentrations by 16% after three days and by 30% after nine days dosing in wild-type mice.

XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase ( SCD1 ) with IC 50 s of 45 and 524 nM in mouse and HepG2 cell, respectively.In VitroXEN723 is a novel and potent thiazolylimidazolidinone inhibitor of

XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase ( SCD1 ) with IC 50 s of 45 and 524 nM in mouse and HepG2 cell, respectively.In VitroXEN723 is a novel and potent thiazolylimidazolidinone inhibitor of

XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase ( SCD1 ) with IC 50 s of 45 and 524 nM in mouse and HepG2 cell, respectively.In VitroXEN723 is a novel and potent thiazolylimidazolidinone inhibitor of

XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase ( SCD1 ) with IC 50 s of 45 and 524 nM in mouse and HepG2 cell, respectively.In VitroXEN723 is a novel and potent thiazolylimidazolidinone inhibitor of